Pacific Biosciences of California market cap is $831 m, and annual revenue was $78.63 m in FY 2018

Pacific Biosciences of California Gross profit (Q3, 2019)6.9 M

Pacific Biosciences of California Gross profit margin (Q3, 2019), %31.5%

Pacific Biosciences of California Net income (Q3, 2019)-29.1 M

Pacific Biosciences of California EBIT (Q3, 2019)-28.1 M

Pacific Biosciences of California Cash, 30-Sept-201933.1 M

Pacific Biosciences of California EV872 M

Pacific Biosciences of California revenue was $78.63 m in FY, 2018

Pacific Biosciences of California revenue breakdown by geographic segment: 56.0% from North America, 22.1% from Europe and 21.9% from Asia

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Revenue | 33.9m | 26.0m | 28.2m | 60.6m | 92.8m | 90.7m | 93.5m | 78.6m |

| 115% | 53% | (2%) | |||||

## Cost of goods sold | 20.8m | 25.0m | 21.8m | 37.2m | 39.3m | 46.6m | 58.8m | 53.5m |

## Gross profit | 13.0m | 940.0k | 6.4m | 23.4m | 53.5m | 44.2m | 34.7m | 25.1m |

| 38% | 4% | 23% | 39% | 58% | 49% | 37% | 32% |

## R&D expense | 76.1m | 47.6m | 45.2m | 48.2m | 60.4m | 67.6m | 65.3m | 62.6m |

## General and administrative expense | 46.7m | 47.7m | 38.7m | 38.0m | 45.2m | 47.8m | 59.1m | 63.5m |

## Operating expense total | 122.8m | 95.3m | 84.0m | 86.3m | 82.6m | 115.4m | 124.4m | 126.1m |

## EBIT | (109.8m) | (94.3m) | (77.5m) | (62.9m) | (29.1m) | (71.2m) | (89.8m) | (101.0m) |

| (324%) | (363%) | (275%) | (104%) | (31%) | (79%) | (96%) | (128%) |

## Pre tax profit | (103.1m) | |||||||

## Net Income | (109.4m) | (94.5m) | (79.3m) | (66.2m) | (31.7m) | (74.4m) | (92.2m) | (102.6m) |

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Net Income | (109.4m) | (94.5m) | (79.3m) | (66.2m) | (31.7m) | (74.4m) | (92.2m) | (102.6m) |

## Depreciation and Amortization | 5.8m | 6.6m | 5.6m | 4.2m | 3.7m | 3.9m | 8.4m | 7.2m |

## Accounts Receivable | (4.2m) | 1.7m | 76.0k | (660.0k) | (1.7m) | (6.2m) | (2.0m) | 4.8m |

## Inventories | (11.4m) | 4.8m | (60.0k) | (1.3m) | (2.5m) | (6.2m) | (8.4m) | 3.6m |

## Accounts Payable | (4.8m) | (1.8m) | (1.3m) | 3.9m | (716.0k) | 3.4m | 764.0k | (2.2m) |

## Cash From Operating Activities | (103.0m) | (76.8m) | (29.8m) | (51.5m) | (47.9m) | (67.9m) | (67.5m) | (66.4m) |

## Purchases of PP&E | (9.3m) | (1.7m) | (909.0k) | (1.6m) | (3.0m) | (8.2m) | (10.4m) | (1.9m) |

## Cash From Investing Activities | 6.4m | 61.8m | (33.1m) | 19.6m | 8.6m | (14.9m) | (1.5m) | (38.4m) |

## Short-term Borrowings | (4.5m) | |||||||

## Cash From Financing Activities | 7.7m | 2.7m | 42.8m | 42.0m | 36.5m | 65.9m | 68.8m | 107.2m |

## Net Change in Cash | (88.8m) | (12.3m) | (20.2m) | 10.1m | (2.8m) | (16.9m) | (258.0k) | 2.3m |

## Interest Paid | 1.2m | 1.8m | 1.8m | 1.8m | 1.7m | 1.4m |

- Source: SEC Filings

- Source: SEC Filings

USD | Y, 2019 |
---|---|

## EV/EBIT | -31 x |

## EV/CFO | -14.5 x |

## Financial Leverage | 2.9 x |

FY, 2016 | |
---|---|

## Patents (Foreign) | 133 |

## Patents (US) | 221 |

## Patents Pending | 187 |

- Source: SEC Filings